semaglutide 9 MG Oral Tablet

RxCUI: 2707555
RxNorm name: semaglutide 9 MG Oral Tablet
Display name: semaglutide 9 MG Oral Tablet
Full name: semaglutide 9 MG Oral Tablet
Term type: SCD
Status: DailyMed mapping
Updated: 2026-06-04 23:39:27

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
OZEMPIC	ORAL SEMAGLUTIDE	Novo Nordisk Pharmaceutical Industries, LP	27f15fac-7d98-4114-a2ec-92494a91da98	2026-01-30	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 2707555

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 2 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
ee06186f-2aa3-4990-a760-757579d8f77b	semaglutide 9 MG Oral Tablet [PSN] · semaglutide 9 MG Oral Tablet [SCD]	2	18	These highlights do not include all the information needed to use WEGOVY ® safely and effectively. See full prescribing information for WEGOVY. WEGOVY (semaglutide) injection, for subcutaneous use WEGOVY (semaglutide) tablets, for oral use Initial U.S. Approval: 2017	20260505
27f15fac-7d98-4114-a2ec-92494a91da98	semaglutide 9 MG Oral Tablet [PSN] · semaglutide 9 MG Oral Tablet [SCD]	2	13	These highlights do not include all the information needed to use RYBELSUS ® and OZEMPIC ® tablets safely and effectively. See full prescribing information for RYBELSUS and OZEMPIC tablets. RYBELSUS (semaglutide) tablets, for oral use OZEMPIC (semaglutide) tablets, for oral use Initial U.S. Approval: 2017	20260130